RENSCHLER MARKUS MD 4
4 · Cyteir Therapeutics, Inc. · Filed Nov 22, 2023
Insider Transaction Report
Form 4
RENSCHLER MARKUS MD
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2023-11-20$1.69/sh+56,737$95,886→ 1,045,473 total - Exercise/Conversion
Common Stock
2023-11-20$1.20/sh+27,900$33,480→ 1,073,373 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-11-20−56,737→ 245,863 totalExercise: $1.69Exp: 2033-02-03→ Common Stock (56,737 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-11-20−27,900→ 5,073 totalExercise: $1.20Exp: 2030-02-24→ Common Stock (27,900 underlying)
Footnotes (3)
- [F1]Includes 5,000 shares of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on January 17, 2023.
- [F2]The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
- [F3]The option vests as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.